Sabril

Known as: Sabrilex 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2016
01219912016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
OBJECTIVES To determine time to vigabatrin (VGB, Sabril; Lundbeck, Deerfield, IL) induced retinal damage in children with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2010
Review
2010
Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages… (More)
Is this relevant?
Review
2007
Review
2007
This article presents a litterature overview of the ophthalmologic secondary effects due to Sabril. First, a review of the visual… (More)
Is this relevant?
2004
2004
PURPOSE A case control study was conducted to assess the effect of Sabril (Vigabatrin), Lamictal (Lamotrigine) and Neurontin… (More)
  • table 3
  • table 5
  • table 4
  • table 4
Is this relevant?
2000
2000
Purpose: Vigabatrin (Sabril), a drug that blocks GABA transaminase, has been used in the treatment of epilepsy since 1989. There… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
1997
1997
Vigabatrin (VGB) has been shown through several studies to be safe and effective as add-on therapy, particularly for the… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
1996
Review
1996
PURPOSE The efficacy and tolerability of vigabatrin (VGB) as an add-on therapy in the treatment of infantile spasm (IS) prompted… (More)
Is this relevant?
1995
1995
Vigabatrin (VGB) prevents seizures by irreversible inhibition of gamma-aminobutyric acid (GABA) transaminase and a resulting… (More)
Is this relevant?
1993
1993
Vigabatrin (Sabril) is a gamma-aminobutyric acid-transaminase (GABA-T) inhibitor that is effective in the treatment of certain… (More)
Is this relevant?
1993
1993
The novel antiepileptic drug vigabatrin (Sabril) acts by inhibiting degradation of the inhibitory neurotransmitter gamma… (More)
Is this relevant?